RA Capital Management, L.P., Director, 10% Owner at Parabilis Medicines, Inc. (PBLS), bought 21,188,750 shares at $20.00 ($423.8M) on 2026-06-11, disclosed to the SEC on 2026-06-15.
RA Capital Management purchased nearly 20 million shares at $20.00, representing the largest insider transaction in Parabilis Medicines' history. This significant buyback suggests the firm views the recent 10% single-day decline as a valuation opportunity in the clinical-stage biopharmaceutical.
The stock recently closed at $27.26, reflecting a sharp single-day decline of approximately 10% on June 15, 2026, despite soaring during its Nasdaq debut earlier in the week.
The company reported a net loss of $209.706 million with no revenue, highlighting the inherent risk of investing in a clinical-stage biopharmaceutical with no current income stream.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.00 | 1,460,397 | $29.2M | 6.9% |
| 2 | $20.00 | 19,728,353 | $394.6M | 93.1% |
| Total | $20.00 avg | 21,188,750 | $423.8M | 100% |
| Filing → |
| ARTV | BUY | 2026-07-31 | $456K | — | Filing → |
| ARTV | BUY | 2026-07-28 | $413K | — | Filing → |
| ARTV | BUY | 2026-07-23 | $58K | — | Filing → |